Penelope Markham
Corporate Officer/Principal chez BIOVIE INC.
Fortune : 25 308 $ au 31/03/2024
Profil
Penelope Markham founded Influx, Inc. in 1997, where she worked as Research Director from 1997 to 2003.
Dr. Markham also currently works at BioVie, Inc., as Executive Vice President-Liver Disease Research from 2021.
Dr. Markham received her doctorate degree from Rush University, graduate degree from the University of Strathclyde, and undergraduate degree from University College Cork.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
BIOVIE INC. CLASS A
0,08% | 16/02/2023 | 47 841 ( 0,08% ) | 25 308 $ | 31/03/2024 |
Postes actifs de Penelope Markham
| Sociétés | Poste | Début |
|---|---|---|
| BIOVIE INC. | Corporate Officer/Principal | 27/04/2021 |
Anciens postes connus de Penelope Markham
| Sociétés | Poste | Fin |
|---|---|---|
Influx, Inc.
 Influx, Inc. Pharmaceuticals: MajorHealth Technology Influx, Inc. discovers and develops antibiotics for difficult-to-treat infections. The company is headquartered in Chicago, IL. | Founder | 01/01/2003 |
Formation de Penelope Markham
| Rush University | Doctorate Degree |
| University of Strathclyde | Graduate Degree |
| University College Cork | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BIOVIE INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Influx, Inc.
Influx, Inc. Pharmaceuticals: MajorHealth Technology Influx, Inc. discovers and develops antibiotics for difficult-to-treat infections. The company is headquartered in Chicago, IL. | Health Technology |
